Dinna N. Cruz, Rosemarie R. Liquete, Dinna N. Cruz, Ma Antonette de Castro-Lontok, Rosemarie R. Liquete, Bienvenido G. Manlutac, Ma Antonette de Castro-Lontok, Benjamin A. Balmores, Bienvenido G. Manlutac, Benjamin A. Balmores
BACKGROUND. Mycophenolate mofetil (MMF) is proven effective as primary prophylaxis against acute rejection after cadaveric renal transplantation. Unfortunately, even at the recommended dose of 2 g/day, it often causes unwanted complications that commo . . .